One Cost Of Cancer: The Rising Price Of Treatment
This article was originally published in The Pink Sheet Daily
Cancer therapies hit 5 percent of total drug spending for the first time in first half of 2009, Medco says
You may also be interested in...
From the drug industry's point of view, the health care reform bill emerging from the Senate Finance Committee has few negative surprises
Findings that a lower dose of Genentech's Avastin showed a similar treatment effect on progression-free survival as a higher dose in the AVAiL trial in first-line non-small cell lung cancer could impact physician prescribing patterns for the oncologic in lung cancer
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.